ERBB2 and breast cancer: Human epidermal growth factor receptor 2 (HER2)/neu overexpression or amplification is found in approximately 15%–30% of breast cancers, and increased expression of this receptor correlates with poor clinical outcome and resistance to endocrine therapy [2, 3].